Progression free survival and overall survival according to HER2 overexpression/HER2 amplification results
| IHC3+ | IHC ≤2 | FISH ratio ≥2 | FISH ratio <2 | dc-SISH ratio ≥2 | dc-SISH ratio <2 | |
| med PFS (months) | 7.98 | 5.45 | 7.98 | 5.35 | 7.98 | 5.35 |
| HR (95% CI) | 0.62 (0.34 to 1.13) | 0.58 (0.36 to 0.94) | 0.61 (0.39 to 0.95) | |||
| p Value | 0.119 | 0.027 | 0.029 | |||
| med OS (months) | 21.39 | 9.82 | 19.61 | 9.72 | 19.58 | 9.66 |
| HR (95% CI) | 0.42 (0.21 to 0.84) | 0.49 (0.29 to 0.83) | 0.53 (0.33 to 0.85) | |||
| p Value | 0.005 | 0.007 | 0.009 | |||
dc-SISH, dual colour silver enhanced in situ hybridisation; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; med PFS, median progression free survival; med OS, median overall survival.